LATEST DIABETES NEWS IN THE UK
Here are the major new developments in diabetes in the UK as of August 2025:
Summary Table
| Area | What’s New (2025) |
| Type 2 Diabetes Treatment | Early use of SGLT-2 inhibitors, personalised drug matching tool |
| Type 1 Diabetes | First UK approval of immunotherapy drug teplizumab |
| Guidelines | Focus on personalised plans and prevention/remission strategies |
| Technology | Advances in glucose monitoring and gene therapy research |
These innovations represent a dramatic step forward for diabetes care in the UK, focusing on personalisation, prevention, and early intervention for both type 1 and type 2 diabetes.exeterbrc.nihr+6
Here’s the detail:-
- Major Update in Type 2 Diabetes Treatment Guidelines
- The National Institute for Health and Care Excellence (NICE) has announced the biggest shake-up in type 2 diabetes care in a decade (August 2025).
- The new draft guidelines move away from a “one-size-fits-all” model. Instead of automatically starting everyone on the same first-line medicine, doctors are now encouraged to provide personalised treatment plans that take into account individual risk factors and co-existing conditions.
- Access to newer diabetes medicines called SGLT-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) has shifted: they can now be used as first-choice treatments, rather than only after other drugs fail. These medicines not only lower blood sugar but also protect the heart and kidneys.
- For patients unable to take metformin, guidelines recommend starting directly with an SGLT-2 inhibitor.nice+2
- Precision Medicine: Personalised Drug Matching Tool
- Researchers have developed a groundbreaking, low-cost tool using routine clinical measures (like sex, weight, standard blood tests) to predict which glucose-lowering drug will be most effective for each person with type 2 diabetes. This precision medicine model means people are more likely to get the right medication from the start, improving outcomes and potentially reducing complications and NHS costs.ukri+2
- This tool is ready for immediate rollout in clinics and is based on data from over 1 million people with type 2 diabetes in the UK.news.exeter+1
- First Immunotherapy Approved for Type 1 Diabetes: Teplizumab
- The first immunotherapy for type 1 diabetes, teplizumab (Tzield), has been approved in the UK.
- Teplizumab is designed to delay the progression of type 1 diabetes in people (aged 8+) who are at high risk but before they develop symptoms. It works by slowing immune attack on insulin-making cells, potentially delaying the need for insulin by around three years on average.diabetes+2
- The first adult in the UK began treatment with teplizumab in July 2025, marking a milestone for type 1 diabetes care. However, it is not yet routinely available on the NHS.royaldevon+1
- New Prevention and Remission Guidelines
- Updated Scottish guidance (SIGN, March 2025) sets out best practices for prevention, early detection, and non-drug management of people at risk of type 2 diabetes, including those with prediabetes, impaired glucose tolerance, or prior gestational diabetes.
- Technology and Gene Therapy Research
Diabetes UK is funding research into advanced glucose monitoring technologies and gene therapies aimed at both type 1 and type 2 diabetes, with promising early results in trials.diabetes+1
